May 13th 2024
Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Pembrolizumab Misses Survival End Points in mCRPC/NSCLC
March 1st 2023The phase 3 KEYNOTE-641 of pembrolizumab, enzalutamide, and androgen deprivation therapy has been discontinued, and overall survival rates in the phase KEYNOTE-789 study of pembrolizumab, pemetrexed, platinum-based chemotherapy did not meet statistical significance.
Read More
FDA to Review BLA for Perioperative Pembrolizumab/Chemotherapy for Stage II-IIIB NSCLC
March 1st 2023With statistically significant and clinically meaningful event-free survival improvement in patients with stage II-IIIB Non–small cell lung cancer, could perioperative pembrolizumab in combination with chemotherapy become a new treatment option?
Read More
Key Updates in the Changing NSCLC Treatment Landscape
February 10th 2023In the third interview of this series, Edward B. Garon, MD, reviews the treatment landscape in non–small cell lung cancer, with a focus on immunotherapy and the recent approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy.
Read More
Porter Reviews Chemoimmunotherapy Combination Data in NSCLC
February 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jason Porter, MD, discussed the CheckMate 9LA and KEYNOTE-407 trials of chemotherapy combined with immunotherapy in patients with advanced squamous cell lung cancer.
Read More
Clinical Implications of Recent Advancements in Immunotherapy for NSCLC
February 3rd 2023In the third installment of this series, Edward B. Garon, MD, MS, gives a historical overview of first-line immunotherapy options for non–small cell lung cancer, discusses the recent FDA approval of durvalumab/tremelimumab in combination with platinum-based chemotherapy in the same setting, and assesses treatment and research goals in the field.
Watch
Different Types of Biomarker Testing Methods Used in Patients with NSCLC
January 31st 2023Drs Socinski and Sabari explain the different types of testing methods commonly used in their clinical practice and share advice for community oncologists who are testing for biomarkers in their patients with NSCLC.
Watch
The Importance of Molecular Testing Before Adjuvant Therapy for NSCLC
January 24th 2023During a Targeted Oncology case-based roundtable event, Edward S. Kim, MD, MBA, discussed adjuvant therapy options and the use of molecular testing in patients with earlier-stage non–small cell lung cancer. This is the first of 2 articles based on this event.
Read More
Potential Immunotherapy Use in Patients with mNSCLC and RET Alterations
A focused discussion on whether immunotherapy might be an effective treatment option for patients with RET-positive mNSCLC.
Watch
The panel reviews LIBRETTO-001 and ARROW safety data on selpercatinib and pralsetinib in RET fusion-positive mNSCLC, and share their clinical experience in adverse event (AE) management in patients who are receiving one of these therapies.
Watch
Selpercatinib and Pralsetinib for RET Fusion-Positive mNSCLC and Supporting Efficacy Data
Dr Piotrowska outlines the RET tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib, which are available for patients with RET fusion-positive mNSCLC, then Dr Neal follows with a discussion of supporting efficacy data from the LIBRETTO-001 and ARROW trials.
Watch
RET Fusion-Positive mNSCLC: Case 2 Presentation and Molecular Testing Strategies
Joel Neal, MD, presents a second case of a 67-year-old man with no smoking history who was diagnosed with RET-rearranged mNSCLC, while Michelle Shiller, DO, AP/CP, MGP, touches on molecular testing approaches in patients who are suspected of having a RET alteration.
Watch